Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.
Devjit TripathyCarolina Solis-HerreraRobert E J RyderPublished in: Diabetes spectrum : a publication of the American Diabetes Association (2021)
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
Keyphrases
- glycemic control
- type diabetes
- cardiovascular events
- cardiovascular risk factors
- insulin resistance
- cardiovascular disease
- blood glucose
- coronary artery disease
- metabolic syndrome
- adverse drug
- weight loss
- adipose tissue
- high fat diet
- emergency department
- drug induced
- oxidative stress
- randomized controlled trial
- high fat diet induced
- diabetic rats
- combination therapy
- smoking cessation
- electronic health record